Canada - French - Health Canada

apotex inc - chlorhydrate de naltrexone - comprimé - 50mg - chlorhydrate de naltrexone 50mg - opiate antagonists

Canada - French - Health Canada

sterinova inc. - chlorhydrate de naltrexone - comprimé - 50mg - chlorhydrate de naltrexone 50mg - opiate antagonists

Canada - French - Health Canada

teva canada limited - chlorhydrate de naltrexone - comprimé - 50mg - chlorhydrate de naltrexone 50mg - opiate antagonists

European Union - French - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leucémie, lymphocytaire, chronique, b-cell - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Belgium - French - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ibsa farmaceutici italia s.r.l. - diclofénac epolamine 180 mg - eq. diclofénac sodique 139 mg - compresse imprégnée - 140 mg - diclofénac epolamine 180 mg - diclofenac

Switzerland - French - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - acalabrutinibum - gélules - acalabrutinibum 100 mg, cellulosum microcristallinum silicificatum, amylum pregelificatum, carboxymethylamylum natricum a corresp. natrium max. 0.25 mg, magnesii stearas, kapselhülle: gelatina, e 172 (flavum), e 132, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum, pro capsula. - chronisch lymphatische leukämie (cll) - synthetika

Canada - French - Health Canada

astrazeneca canada inc - acalabrutinib - capsule - 100mg - acalabrutinib 100mg - antineoplastic agents

Canada - French - Health Canada

astrazeneca canada inc - acalabrutinib (maléate d¿acalabrutinib) - comprimé - 100mg - acalabrutinib (maléate d¿acalabrutinib) 100mg

Switzerland - French - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - acalabrutinibum - comprimés pelliculés - acalabrutinibum 100 mg ut acalabrutinibi maleas monohydricum, mannitolum, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, natrii stearylis fumaras, Überzug: hypromellosum, copovidonum, e 171, macrogolum 3350, triglycerida media, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium 0.59 mg. - chronisch lymphatische leukämie (cll) - synthetika